The gene transfection properties of a lipophosphoramidate derivative with two phytanyl chains

Biomaterials

Volumn 33, Issue 26, 2012, Pages 6240-6253

  Lindberg, Mattias F ^a   Carmoy, Nathalie ^a   Le Gall, Tony ^a   Fraix, Aurore ^a   Berchel, Mathieu ^a   Lorilleux, Christophe ^a   Couthon Gourvès, Hélène ^a   Bellaud, Pascale ^b   Fautrel, Alain ^b   Jaffrès, Paul Alain ^a   Lehn, Pierre ^a   Montier, Tristan ^a  

^a UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

^b UNIVERSITÉ DE RENNES 1   (France)

Author keywords

Bioluminescence; Cationic lipid; Hepatotoxicity; Lipophosphoramidate; Phytanyl chains; Transfection

Indexed keywords

ADVERSE EFFECT; BIOLUMINESCENT IMAGING; CATIONIC LIPIDS; CELL TYPES; CLINICAL APPLICATION; CYSTIC FIBROSIS; GENE DELIVERY SYSTEMS; GENE TRANSFECTION; HEPATOTOXICITY; HEXAGONAL PHASE; HYDROPHOBIC DOMAINS; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IN-VITRO; IN-VIVO; LIPOPHOSPHORAMIDATE; LIPOPLEXES; LIVING ANIMALS; MOUSE LUNG; NMR STUDIES; SIDE EFFECT; SUPRAMOLECULAR ARRANGEMENT; TRANSFECTION; TRANSFECTION EFFICIENCY; WATER SOLUTIONS;

BIOLOGICAL ORGANS; BIOLUMINESCENCE; EFFICIENCY; GENE THERAPY; GENE TRANSFER;

MOLECULAR BIOLOGY;

2 (O,O DIPHYTANYLPHOSPHATIDYL) AMINOETHYLTRIMETHYARSONIUM IODIDE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; COLONY STIMULATING FACTOR 1; GAMMA INTERFERON; GENE THERAPY AGENT; INTERCELLULAR ADHESION MOLECULE 1; LIPID; LIPOPLEX; O,O DIPHYTANYL N (2 BROMOETHYL)PHOSPHORAMIDIC ACID; O,O DIPHYTANYL N (2 IODOETHYL)PHOSPHORAMIDIC ACID; PHOSPHORAMIDIC ACID DERIVATIVE; PHYTANIC ACID; RANTES; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BIOLUMINESCENCE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; FEMALE; GENE LOCATION; GENE THERAPY; GENE VECTOR; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HYDROPHOBICITY; IMMUNOHISTOCHEMISTRY; IN VITRO GENE TRANSFER; IN VITRO STUDY; IN VIVO GENE TRANSFER; INFLAMMATION; LIVER TOXICITY; LUNG ALVEOLUS EPITHELIUM; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENE;

AMIDES; ANIMALS; CELL LINE; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; IMMUNOHISTOCHEMISTRY; MAGNETIC RESONANCE SPECTROSCOPY; MICE; PHOSPHORIC ACIDS; TRANSFECTION;

ANIMALIA;

EID: 84862893822     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.05.014     Document Type: Article

References (54)

1. Riordan J.R., Rommens J.M., Kerem B., Alon N., Rozmahel R., Grzelczak Z., et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989, 245:1066-1073.
2. Mornon J.-P., Lehn P., Callebaut I. Molecular models of the open and closed states of the whole human CFTR protein. Cell Mol Life Sci 2009, 66:3469-3486.
3. Griesenbach U., Alton E.W.F.W. Current status and future directions of gene and cell therapy for cystic fibrosis. BioDrugs 2011, 25:77-88.
4. Le Gall T., Loizeau D., Picquet E., Carmoy N., Yaouanc J.J., Burel-Deschamps L., et al. A novel cationic lipophosphoramide with diunsaturated lipid chains: synthesis, physicochemical properties, and transfection activities. J Med Chem 2010, 53:1496-1508.
5. Koynova R., Wang L., Macdonald R.C. Cationic phospholipids forming cubic phases: lipoplex structure and transfection efficiency. Mol Pharm 2008, 5:739-744.
6. Zuhorn I.S., Bakowsky U., Polushkin E., Visser W.H., Stuart M.C.A., Engberts J.B.F.N., et al. Nonbilayer phase of lipoplex-membrane mixture determines endosomal escape of genetic cargo and transfection efficiency. Mol Ther 2005, 11:801-810.
7. Tenchov B.G., Wang L., Koynova R., MacDonald R.C. Modulation of a membrane lipid lamellar-nonlamellar phase transition by cationic lipids: a measure for transfection efficiency. Biochim Biophys Acta 2008, 1778:2405-2412.
8. Israelachvili J.N., Mitchell D.J., Ninham B.W. Theory of self-assembly of hydrocarbon amphiphiles into micelles and bilayers. J Chem Soc, Faraday Trans 1976, 72(2):1525-1568.
9. Conn C.E., Panchagnula V., Weerawardena A., Waddington L.J., Kennedy D.F., Drummond C.J. Lanthanide phytanates: liquid-crystalline phase behavior, colloidal particle dispersions, and potential as medical imaging agents. Langmuir 2010, 26:6240-6249.
10. Liu G., Conn C.E., Drummond C.J. Lanthanide oleates: chelation, self-assembly, and exemplification of ordered nanostructured colloidal contrast agents for medical imaging. J Phys Chem B 2009, 113:15949-15959.
11. Berchel M., Le Gall T., Couthon-Gourvès H., Haelters J.-P., Montier T., Midoux P., et al. Lipophosphonate/lipophosphoramidates: a family of synthetic vectors efficient for gene delivery. Biochimie 2012, 94:33-41.
12. Jellum E., Eldjarn L., Try K. Conversion of phytol into dihydrophytol and phytanic acid. Acta Chem Scand 1966, 20:2535-2538.
13. Picquet E., Le Ny K., Delépine P., Montier T., Yaouanc J.-J., Cartier D., et al. Cationic lipophosphoramidates and lipophosphoguanidines are very efficient for in vivo DNA delivery. Bioconjug Chem 2005, 16:1051-1053.
14. Massiot D., Fayon F., Capron M., King I., Le Calvé S., Alonso B., et al. Modelling one- and two-dimensional solid-state NMR spectra. Magn Reson Chem 2002, 40:70-76.
15. Delépine P., Guillaume C., Floch V., Loisel S., Yaouanc J., Clément J., et al. Cationic phosphonolipids as nonviral vectors: in vitro and in vivo applications. J Pharm Sci 2000, 89:629-638.
16. Cullis P.R., de Kruijff B. Lipid polymorphism and the functional roles of lipids in biological membranes. Biochim Biophys Acta 1979, 559:399-420.
17. Koynova R., Tenchov B., Wang L., Macdonald R.C. Hydrophobic moiety of cationic lipids strongly modulates their transfection activity. Mol Pharm 2009, 6:951-958.
18. Rosenzweig H.S., Rakhmanova V.A., McIntosh T.J., MacDonald R.C. O-Alkyl dioleoylphosphatidylcholinium compounds: the effect of varying alkyl chain length on their physical properties and in vitro DNA transfection activity. Bioconjug Chem 2000, 11:306-313.
19. Ewert K.K., Ahmad A., Evans H.M., Safinya C.R. Cationic lipid-DNA complexes for non-viral gene therapy: relating supramolecular structures to cellular pathways. Expert Opin Biol Ther 2005, 5:33-53.
20. Guillaume-Gable C., Floch V., Mercier B., Audrézet M.P., Gobin E., Le Bolch G., et al. Cationic phosphonolipids as nonviral gene transfer agents in the lungs of mice. Hum Gene Ther 1998, 9:2309-2319.
21. Floch V., Delépine P., Guillaume C., Loisel S., Chassé S., Le Bolc'h G., et al. Systemic administration of cationic phosphonolipids/DNA complexes and the relationship between formulation and lung transfection efficiency. Biochim Biophys Acta 2000, 1464:95-103.
22. Felgner P.L., Gadek T.R., Holm M., Roman R., Chan H.W., Wenz M., et al. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci U S A 1987, 84:7413-7417.
23. Hyde S.C., Southern K.W., Gileadi U., Fitzjohn E.M., Mofford K.A., Waddell B.E., et al. Repeat administration of DNA/liposomes to the nasal epithelium of patients with cystic fibrosis. Gene Ther 2000, 7:1156-1165.
24. Montier T., Benvegnu T., Jaffrès P.-A., Yaouanc J.-J., Lehn P. Progress in cationic lipid-mediated gene transfection: a series of bio-inspired lipids as an example. Curr Gene Ther 2008, 8:296-312.
25. Labas R., Beilvert F., Barteau B., David S., Chevre R., Pitard B. Nature as a source of inspiration for cationic lipid synthesis. Genetica 2010, 138:153-168.
26. Midoux P., Pichon C., Yaouanc J.J., Jaffres P.A. Chemical vectors for gene delivery: a current review on polymers, peptides and lipids containing histidine or imidazole as nucleic acids carriers. Br J Pharmacol 2009, 157:166-178.
27. Grosse S., Thévenot G., Aron Y., Duverger E., Abdelkarim M., Roche A.-C., et al. In vivo gene delivery in the mouse lung with lactosylated polyethylenimine, questioning the relevance of in vitro experiments. J Control Release 2008, 132:105-112.
28. Zhi D., Zhang S., Wang B., Zhao Y., Yang B., Yu S. Transfection efficiency of cationic lipids with different hydrophobic domains in gene delivery. Bioconjug Chem 2010, 21:563-577.
29. Laurent V., Fraix A., Montier T., Cammas-Marion S., Ribault C., Benvegnu T., et al. Highly efficient gene transfer into hepatocyte-like HepaRG cells: new means for drug metabolism and toxicity studies. Biotechnol J 2010, 5:314-320.
30. Koynova R., Wang L., MacDonald R.C. An intracellular lamellar-nonlamellar phase transition rationalizes the superior performance of some cationic lipid transfection agents. Proc Natl Acad Sci USA 2006, 103:14373-14378.
31. Corsi J., Hawtin R.W., Ces O., Attard G.S., Khalid S. DNA lipoplexes: formation of the inverse hexagonal phase observed by coarse-grained molecular dynamics simulation. Langmuir 2010, 26:12119-12125.
32. Koynova R., Wang L., Tarahovsky Y., MacDonald R.C. Lipid phase control of DNA delivery. Bioconjug Chem 2005, 16:1335-1339.
33. Wang L., Koynova R., Parikh H., MacDonald R.C. Transfection activity of binary mixtures of cationic o-substituted phosphatidylcholine derivatives: the hydrophobic core strongly modulates physical properties and DNA delivery efficacy. Biophys J 2006, 91:3692-3706.
34. Koynova R., Tenchov B. Cationic phospholipids: structure-transfection activity relationships. Soft Matter 2009, 5:3187-3200.
35. Matulis D., Rouzina I., Bloomfield V.A. Thermodynamics of cationic lipid binding to DNA and DNA condensation: roles of electrostatics and hydrophobicity. J Am Chem Soc 2002, 124:7331-7342.
36. Kennedy M.T., Pozharski E.V., Rakhmanova V.A., MacDonald R.C. Factors governing the assembly of cationic phospholipid-DNA complexes. Biophys J 2000, 78:1620-1633.
37. Davies L.A., Seguela C., Varathalingam A., Cheng S.H., Hyde S.C., Gill D.R. Identification of transfected cell types following non-viral gene transfer to the murine lung. J Gene Med 2007, 9:184-196.
38. Dif F., Djediat C., Alegria O., Demeneix B., Levi G. Transfection of multiple pulmonary cell types following intravenous injection of PEI-DNA in normal and CFTR mutant mice. J Gene Med 2006, 8:82-89.
39. Griesenbach U., Chonn A., Cassady R., Hannam V., Ackerley C., Post M., et al. Comparison between intratracheal and intravenous administration of liposome-DNA complexes for cystic fibrosis lung gene therapy. Gene Ther 1998, 5:181-188.
40. Delépine P., Guillaume C., Montier T., Clément J.C., Yaouanc J.J., Des Abbayes H., et al. Biodistribution study of phosphonolipids: a class of non-viral vectors efficient in mice lung-directed gene transfer. J Gene Med 2003, 5:600-608.
41. Li S., Tseng W.C., Stolz D.B., Wu S.P., Watkins S.C., Huang L. Dynamic changes in the characteristics of cationic lipidic vectors after exposure to mouse serum: implications for intravenous lipofection. Gene Ther 1999, 6:585-594.
42. Loisel S., Le Gall C., Doucet L., Ferec C., Floch V. Contribution of plasmid DNA to hepatotoxicity after systemic administration of lipoplexes. Hum Gene Ther 2001, 12:685-696.
43. Ito Y., Kawakami S., Charoensit P., Higuchi Y., Hashida M. Evaluation of proinflammatory cytokine production and liver injury induced by plasmid DNA/cationic liposome complexes with various mixing ratios in mice. Eur J Pharm Biopharm 2009, 71:303-309.
44. Kawakami S., Ito Y., Fumoto S., Yamashita F., Hashida M. Enhanced gene expression in lung by a stabilized lipoplex using sodium chloride for complex formation. J Gene Med 2005, 7:1526-1533.
45. Kako K., Nishikawa M., Yoshida H., Takakura Y. Effects of inflammatory response on in vivo transgene expression by plasmid DNA in mice. J Pharm Sci 2008, 97:3074-3083.
46. McLachlan G., Davidson H., Holder E., Davies L.A., Pringle I.A., Sumner-Jones S.G., et al. Pre-clinical evaluation of three non-viral gene transfer agents for cystic fibrosis after aerosol delivery to the ovine lung. Gene Ther 2011, 18:996-1005.
47. Ruiz F.E., Clancy J.P., Perricone M.A., Bebok Z., Hong J.S., Cheng S.H., et al. A clinical inflammatory syndrome attributable to aerosolized lipid-DNA administration in cystic fibrosis. Hum Gene Ther 2001, 12:751-761.
48. Sakurai H., Kawabata K., Sakurai F., Nakagawa S., Mizuguchi H. Innate immune response induced by gene delivery vectors. Int J Pharm 2008, 354:9-15.
49. Yasuda S., Yoshida H., Nishikawa M., Takakura Y. Comparison of the type of liposome involving cytokine production induced by non-CpG Lipoplex in macrophages. Mol Pharm 2010, 7:533-542.
50. Conwell C.C., Liu F., Huang L. Several serum proteins significantly decrease inflammatory response to lipid-based non-viral vectors. Mol Ther 2008, 16:370-377.
51. Wilson K.D., Raney S.G., Sekirov L., Chikh G., deJong S.D., Cullis P.R., et al. Effects of intravenous and subcutaneous administration on the pharmacokinetics, biodistribution, cellular uptake and immunostimulatory activity of CpG ODN encapsulated in liposomal nanoparticles. Int Immunopharmacol 2007, 7:1064-1075.
52. Hyde S.C., Pringle I.A., Abdullah S., Lawton A.E., Davies L.A., Varathalingam A., et al. CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression. Nat Biotechnol 2008, 26:549-551.
53. Bazzani R.P., Cai Y., Hebel H.L., Hyde S.C., Gill D.R. The significance of plasmid DNA preparations contaminated with bacterial genomic DNA on inflammatory responses following delivery of lipoplexes to the murine lung. Biomaterials 2011, 32:9854-9865.
54. Alton E.W., Stern M., Farley R., Jaffe A., Chadwick S.L., Phillips J., et al. Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial. Lancet 1999, 353:947-954.